Subclinical inflammation precedes atopic dermatitis relapses
- PMID: 40562080
- DOI: 10.1016/j.jaci.2025.03.033
Subclinical inflammation precedes atopic dermatitis relapses
Abstract
Background: Atopic dermatitis (AD), a widespread inflammatory skin disease, is characterized by disease recurrence, even after successful treatment. Past clinical research has mainly focused on understanding the active disease state as opposed to what drives and triggers AD relapses in the first place.
Objectives: We sought to elucidate the unknown molecular mechanisms behind AD relapses.
Methods: An observational clinical study with patients in remission was conducted, comparing biopsies from skin that would relapse within the next weeks with skin that stayed in remission using single-cell RNA-sequencing and immunohistochemistry analyses.
Results: Signs of subclinical inflammation were present in the clinically healthy appearing prerelapse state: On the one hand, we detected molecular signals reminiscent of active AD, such as epidermal barrier dysregulation, chemokine signaling, increased vascular permeability, and first signs of T-cell activity and infiltration. On the other hand, we also observed signals for processes specific to the prerelapse state, including EGFR signaling and macrophage phagocytosis.
Conclusion: Taken together, this work uncovers novel aspects of AD development and putatively paves the way for new therapeutic approaches that are specifically designed to prevent AD recurrence.
Keywords: Atopic dermatitis; atopic dermatitis relapse; prerelapse state; single-cell sequencing; subclinical inflammation.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure statement This project and the position of S.F. were funded by Beiersdorf AG. Disclosure of potential conflict of interest: B. Al, N. Holzscheck, H. Mießner, H. Reuter, and J.A. Seidel are employees at the Beiersdorf AG. T. Werfel has received institutional research grants from Beiersdorf, LEO Pharma, and Novartis; has performed consultancies for AbbVie, Almirall, Janssen, Galderma, LEO, Lilly, Novartis, Pfizer, and Sanofi-Regeneron; has lectured at educational events sponsored by AbbVie, Janssen, Celgene, Galderma, LEO Pharma, Lilly, Sanofi, and Novartis; and is involved in performing clinical trials for various pharmaceutical industries that manufacture drugs used for the treatment of atopic dermatitis. S. Traidl has performed/lectured at educational events by Janssen, LEO, Lilly, Sanofi-Regeneron, and LaRoche-Posay. L.M. Roesner has received institutional research grants from Novartis and Almirall; has performed consultancies for Almirall; and has lectured at educational events for Novartis. Based on the results of this study a patent has been filed (Publication number: EP4163638-A3). The rest of the authors declare that they have no relevant conflicts of interest.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous